Literature DB >> 10636883

Interactions between HIV-1 gp41 core and detergents and their implications for membrane fusion.

W Shu1, H Ji, M Lu.   

Abstract

The gp41 envelope protein mediates entry of human immunodeficiency virus type 1 (HIV-1) into the cell by promoting membrane fusion. The crystal structure of a gp41 ectodomain core in its fusion-active state is a six-helix bundle in which a N-terminal trimeric coiled coil is surrounded by three C-terminal outer helices in an antiparallel orientation. Here we demonstrate that the N34(L6)C28 model of the gp41 core is stabilized by interaction with the ionic detergent sodium dodecyl sulfate (SDS) or the nonionic detergent n-octyl-beta-D-glucopyranoside (betaOG). The high resolution x-ray structures of N34(L6)C28 crystallized from two different detergent micellar media reveal a six-helix bundle conformation very similar to that of the molecule in water. Moreover, N34(L6)C28 adopts a highly alpha-helical conformation in lipid vesicles. Taken together, these results suggest that the six-helix bundle of the gp41 core displays substantial affinity for lipid bilayers rather than unfolding in the membrane environment. This characteristic may be important for formation of the fusion-active gp41 core structure and close apposition of the viral and cellular membranes for fusion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10636883     DOI: 10.1074/jbc.275.3.1839

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Kinetically coupled folding of a single HIV-1 glycoprotein 41 complex in viral membrane fusion and inhibition.

Authors:  Junyi Jiao; Aleksander A Rebane; Lu Ma; Ying Gao; Yongli Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-18       Impact factor: 11.205

2.  Dissociation of the trimeric gp41 ectodomain at the lipid-water interface suggests an active role in HIV-1 Env-mediated membrane fusion.

Authors:  Julien Roche; John M Louis; Alexander Grishaev; Jinfa Ying; Adriaan Bax
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-18       Impact factor: 11.205

3.  HIV infection upregulates caveolin 1 expression to restrict virus production.

Authors:  Shanshan Lin; Xiao Mei Wang; Peter E Nadeau; Ayalew Mergia
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

4.  Structure-based design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41.

Authors:  Yong Wang; Hong Lu; Qiang Zhu; Shibo Jiang; Yun Liao
Journal:  Bioorg Med Chem Lett       Date:  2009-11-05       Impact factor: 2.823

5.  Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition.

Authors:  Yuxian He; Shuwen Liu; Jingjing Li; Hong Lu; Zhi Qi; Zhonghua Liu; Asim K Debnath; Shibo Jiang
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

Review 6.  HIV-1 envelope glycoprotein structure.

Authors:  Alan Merk; Sriram Subramaniam
Journal:  Curr Opin Struct Biol       Date:  2013-04-18       Impact factor: 6.809

7.  Hairpin folding of HIV gp41 abrogates lipid mixing function at physiologic pH and inhibits lipid mixing by exposed gp41 constructs.

Authors:  Kelly Sackett; Matthew J Nethercott; Yechiel Shai; David P Weliky
Journal:  Biochemistry       Date:  2009-03-31       Impact factor: 3.162

8.  Peptide mimic of the HIV envelope gp120-gp41 interface.

Authors:  Sunghwan Kim; Hong-Bo Pang; Michael S Kay
Journal:  J Mol Biol       Date:  2007-12-07       Impact factor: 5.469

9.  Interaction of HIV-1 gp41 core with NPF motif in Epsin: implication in endocytosis of HIV.

Authors:  Jing-He Huang; Zhi Qi; Fan Wu; Leszek Kotula; Shibo Jiang; Ying-Hua Chen
Journal:  J Biol Chem       Date:  2008-03-28       Impact factor: 5.157

10.  Computer-Aided Approaches for Targeting HIVgp41.

Authors:  William J Allen; Robert C Rizzo
Journal:  Biology (Basel)       Date:  2012-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.